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Abstract: 
Salen Mn complexes, including EUK-134, EUK-189 and a newer 
cyclized analog EUK-207, are synthetic SOD/catalase mimetics that have 
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beneficial effects in many models of oxidative stress. As oxidative stress is 
implicated in some forms of delayed radiation injury, we are investigating 
whether these compounds can mitigate injury to normal tissues caused by 
ionizing radiation. This review describes some of this research, focusing on 
several tissues of therapeutic interest, namely kidney, lung, skin, and oral 
mucosa. These studies have demonstrated suppression of delayed radiation 
injury in animals treated with EUK-189 and/or EUK-207. While an antioxidant 
mechanism of action is postulated, it is likely that the mechanisms of 
radiation mitigation by these compounds in vivo are complex and may differ 
in the various target tissues. Indicators of oxidative stress are increased in 
lung and skin radiation injury models, and suppressed by salen Mn 
complexes. The role of oxidative stress in the renal injury model is unclear, 
though EUK-207 does mitigate. In certain experimental models, salen Mn 
complexes have shown “mito-protective” properties, that is, attenuating 
mitochondrial injury. Consistent with this, EUK-134 suppresses effects of 
ionizing radiation on mitochondrial function in rat astrocyte cultures. In 
summary, salen Mn complexes could be useful to mitigate delayed radiation 
injury to normal tissues following radiation therapy, accidental exposure, or 
radiological terrorism. Optimization of their mode of delivery and other key 
pharmaceutical properties, and increasing understanding of their 
mechanism(s) of action as radiation mitigators, are key issues for future 
study. 
Keywords: salen manganese complex, radiation injury, radiation mitigation, 
catalytic antioxidant. 
II. Rationale for testing Salen Mn complexes as 
radiation mitigators 
Radiation therapy, besides destroying the tumor cells that are 
its intended target, can also cause delayed injuries, some very serious 
or even lethal, to normal tissues. There is a need for therapeutic 
agents to prevent such normal tissue injury. Preferably, these agents 
would be administered well after irradiation, so as not to risk 
interfering with the anti-tumor effects of the radiation therapy [1]. 
While the mechanisms of delayed radiation injury are not well 
understood, evidence suggests that oxidative stress is involved [2–4]. 
Therefore, we and others have studied synthetic agents that neutralize 
the reactive oxygen species (ROS) superoxide and hydrogen peroxide 
as potential therapeutic agents to mitigate normal tissue injury 
resulting from ionizing radiation. This review focuses primarily on 
radiation mitigation studies employing one class of synthetic ROS 
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scavenger, a class of synthetic metal-containing compounds known as 
salen Mn complexes [5]. 
It has long been known that exposure of biological materials to 
ionizing radiation produces a burst of reactive oxygen species (ROS), 
including superoxide, hydrogen peroxide, hydroxyl radical, and singlet 
oxygen. These highly reactive species oxidize cellular macromolecules, 
such as DNA, producing lethal damage [6]. However, what has been 
less appreciated until recently is the potential role of chronically 
generated ROS in delayed radiation-induced damage [2–4]. Such 
injury, including fibrosis, necrosis, atrophy, and vascular damage, 
occurs months to years after exposure to radiation. Clinically relevant 
target tissues for radiation injury include the skin, kidney, lung, oral 
mucosa and brain. There is evidence for cumulative ROS and reactive 
nitrogen species (RNS)-mediated damage, for example lipid 
peroxidation and protein tyrosine nitration, in such target tissues 
following irradiation. There is also evidence for proinflammatory 
processes, namely acute activation of stress-sensitive signaling 
transcriptional events and cytokine production [4, 7]. Indeed, 
infiltrating inflammatory cells would serve as one likely source of 
damaging ROS. Another potential source of ROS is the mitochondria, 
especially when dysfunctional. Evidence indicates not only that 
radiation leads to mitochondrial injury, but also that delivery of 
antioxidant enzymes to the mitochondria through gene therapy 
techniques can protect against delayed radiation damage in vivo [2], 
and a mitochondrially targeted antioxidant reduces radiation injury in 
cell culture [8]. Therefore, both proinflammatory processes and 
mitochondrial dysfunction are implicated in delayed radiation injury. 
These findings suggest that agents that interrupt these damaging 
subcellular processes might have considerable therapeutic benefit 
against the damaging effects of radiation exposure. 
Such considerations have led to our investigation of salen Mn 
complexes as potential mitigators of delayed radiation injury. As 
discussed further below, prior data showed that treatment with these 
compounds suppressed proinflammatory processes, inhibited 
mitochondrial damage, and reduced oxidative changes in various 
experimental models not involving radiation injury. 
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Currently the only FDA-approved drug for preventing radiation 
injury is amifostine (Ethylol®), which is usually administered 
intravenously or subcutaneously and, according to current clinical 
guidelines, prior to radiation exposure [9]. It acts as a free radical 
scavenger, but may have additional mechanisms of action such as 
modulation of antioxidant enzymes [9, 10]. No agent has yet been 
FDA-approved to prevent radiation injury when administered after 
radiation, a property referred to as “radiation mitigation”. In the 
radiation countermeasures area, mitigators refer to therapies begun 
after irradiation but prior to clinical evidence of injury. This is to 
distinguish them from protectors, which are given prior to irradiation, 
and from treatment agents, which are used after there is clinical 
evidence of injury [11]. Salen Mn complexes, while not yet approved 
for human use, are interesting candidates for development with 
potential advantages over amifostine. One major advantage is their 
ability, as summarized in this review, to mitigate delayed radiation 
injury when given days to weeks after irradiation. 
Salen Mn complexes are a class of synthetic low molecular 
weight agents that mimic the antioxidant enzymes superoxide 
dismutase (SOD) and catalase, scavenging superoxide and hydrogen 
peroxide, respectively [5]. Data, including structure-activity 
relationship findings in vitro and in vivo, indicate that the hydrogen 
peroxide scavenging property, namely catalase activity, is a more 
important parameter than SOD activity in determining certain 
cytoprotective effects of salen Mn complexes, though other factors 
such as pharmacokinetics and cytotoxicity are also important [5]. In 
addition, it’s been shown that salen Mn complexes can scavenge 
reactive nitrogen species (RNS) through mechanisms analogous to 
their catalase activity [12], a property of potential relevance to their 
ability to attenuate protein nitration in oxidative injury models [13, 
14]. Overall, this combination of properties (low molecular weight, 
catalytic scavenging mechanism, and activity against multiple 
damaging species) provides advantages for salen Mn complexes over 
other antioxidants, such as noncatalytic ROS scavengers or 
proteinacious antioxidant enzymes [15, 16]. Prototype salen Mn 
complexes EUK-8 and the improved catalase mimetics EUK-134 and 
EUK-189 (Fig 1), are effective in a wide range of models for diseases 
involving oxidative stress [6, 17]. In many of these models, salen Mn 
complexes were not only functionally protective, but also suppressed 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
6 
 
biochemical indicators of oxidative stress, such as oxidative 
modifications of protein, lipids and nucleic acids [13, 18, 19]. EUK-207 
(Fig 1) is a “second generation” cyclized salen Mn complex that has 
catalytic properties equivalent to EUK-134 and EUK-189, but was 
designed for greater stability [17, 18, 20]. Consistent with this, we 
have found that EUK-207 attains much higher plasma levels than EUK-
189 (e.g., when given subcutaneously to rats (Fig 2)). Both EUK-189 
and EUK-207 are highly effective at improving a behavioral indicator of 
cognitive function and suppressing markers for brain oxidative stress 
(e.g. nucleic acid oxidation) in a mouse model for age-associated mild 
cognitive impairment [18, 21]. While structure-activity relationship 
data and other relevant properties have been published for these 
compounds, Table 1 is included to facilitate their comparison. The 
Table summarizes key properties of EUK-189 and EUK-207, as well as 
Mn porphyrin compounds that are discussed in section IV. 
Endogenous antioxidant defense enzymes [6] include three 
types of superoxide dismutases (SOD). The cytosolic and extracellular 
forms of superoxide dismutase (sod1 and sod3, respectively) are Cu 
and Zn containing enzymes. The mitochondrial form (sod2, or MnSOD) 
instead has Mn in its active site. Mitochondria-targeted expression of 
either sod2 or sod1 protects against radiation injury in a mouse 
esophagitis model [2, 22] and mice deficient in sod2 (sod2−/+ mice) 
are more vulnerable to radiation lung injury [23]. A mutation leading 
to increased production of mitochondria-derived ROS has recently 
been shown to make mammalian cells (hamster fibroblasts) 
substantially more sensitive to ionizing radiation, and it’s been 
hypothesized that radiation-induced disruptions in mitochondrial 
oxygen metabolism contributes to radiation injury [24]. Such findings 
suggest that a synthetic antioxidant reaching the mitochondria should 
have therapeutic benefits in radiation injury. Although salen Mn 
complexes were not designed specifically to target the mitochondria, 
several studies have shown that the compounds are, indeed, “mito-
protective”. They prolong survival up to 3-fold, protect mitochondrial 
enzymes, and prevent oxidative pathologies in sod2−/− mice, an in 
vivo model for severe mitochondrial oxidative stress [25, 26]. EUK-189 
and EUK-207 were much more effective than other agents tested in 
sod2−/− mice, namely, the Mn porphyrin MnTBAP, the reported SOD 
mimetic M40403, and the mitochondrial metabolites, with reported 
mitoprotective properties, alpha lipoic acid and L-acetyl-carnitine [17]. 
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Since salen Mn complexes, unlike targeted agents such as MitoQ [27] 
and others [8] are not designed to exclusively reach the mitochondria, 
they might have broader therapeutic potential because, presumably, 
they can also address non-mitochondrial injury mechanisms, such as 
proinflammatory processes. 
Irradiation of late-responding tissues leads to acute activation of 
stress-responsive transcriptional events, leading to production of 
inflammatory cytokines mediating an aberrant chronic inflammatory 
cascade that ultimately leads to fibrosis or necrosis [4, 7] Production 
of such mediators is controlled by “stress-induced” transcriptional 
factors including those, e.g. NF-kB and AP-1, which are believed to be 
activated by increased ROS. Such events are reminiscent of 
proinflammatory processes that mediate tissue injury in many other 
pathological conditions, such as infection, ischemia/excitotoxicity, and 
environmental stress. Salen Mn complexes are markedly protective 
against such forms of tissue injury in vivo, while concomitantly 
suppressing activation of “stress-induced” transcription factors in 
target tissues [13, 28, 29]. For example, EUK-134 inhibited the 
excitotoxic activation of AP-1 and NF-κB secondary to kainic acid-
induced seizures, while preventing hippocampal neuronal death [13]. 
EUK-189 inhibited AP-1 activation in aged rats subjected to mild heat-
stress, while concomitantly preventing severe liver injury that occurs 
in aged, but not young, rats in this experimental system [30]. Salen 
Mn complex treatment increased the mean survival time of allogeneic 
C57Bl/6 skin grafted into BALB/c mice, reduced pro-inflammatory type 
1 alloresponse (IFN-γ) while promoting anti inflammatory type 2 
alloimmunity (IL-4 and IL-5) [31]. Tissue transglutamininase 2 is 
activated in a pro-oxidative environment, inducing degradation of 
PPAR-γ, NF-κB activation and inflammation [32] and treatment with 
EUK-134 restored PPAR-γ, levels [33]. Therefore, the suppressive 
effects of salen Mn complexes against proinflammatory, injury-
associated transcriptional processes provided another rationale, in 
addition to their “mito-protective” properties, for investigating their 
benefits in radiation injury models. 
Taken together, such findings led to the hypothesis that salen 
Mn complexes would mitigate radiation injury to normal tissues. 
Proposed mechanisms might involve preventing mitochondrial injury, 
suppressing “proinflammatory” processes, inhibiting other forms of 
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oxidative injury to cellular constituents or most likely, complex 
combinations thereof. 
III. Mitigation of radiation injury by salen Mn 
complexes 
Cell culture systems 
Mitochondrial dysfunction in astrocytes as a model for central 
nervous system (CNS) radiation injury - Radiotherapy continues to 
be a primary treatment for malignant brain tumors as well as other 
neoplasms located in or near the CNS. Consequently, radiation-
induced injury to normal CNS tissue is of significant concern and is the 
major dose-limiting factor in the treatment of gliomas and other head 
and neck tumors. The CNS damage resulting from irradiation is most 
often characterized by vascular abnormalities, demyelination and, 
ultimately, necrosis, which can be expressed years after radiotherapy 
[34]. Although this form of radiation-induced normal tissue injury has 
been well described in terms of histological and functional criteria [35, 
36], its pathogenesis remains poorly understood. Delayed cell death 
and tissue injury can result from a number of reactive processes, but 
accumulating data suggest that an initiating source of these delayed 
effects can be mitochondrial dysfunction. Mitochondrial damage has 
been implicated in a number of neurological conditions, namely 
trauma, ischemia, excitotoxic insults and neurodegeneration, and CNS 
lesions following radiation share some similarity to these other forms 
of injury [37]. The ultimate consequences of mitochondrial injury 
include insufficient ATP production and increased ROS generation. With 
its high energy demands and rate of oxidative metabolism, the CNS is 
particularly susceptible to these impairments. Rat astrocyte cultures 
were used to investigate the role of mitochondrial dysfunction in CNS 
radiation injury. Astrocytes are the most prevalent phenotype in the 
CNS, outnumbering neurons by approximately 9:1. They have 
numerous functions in the normal CNS [38] including a critical role in 
the protection of endothelial cells, oligodendrocytes and neurons from 
oxidative or excitotoxic injury [39–41]. Given their key functions, it 
would be expected that the response of astrocytes to radiation would 
have a major impact on the radiation response of the CNS as a whole. 
The astrocytes, which are normally relatively non-proliferative in vivo, 
were tested for radiation injury as confluent cultures, thus eliminating 
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the complicating variables of cell cycle delay and redistribution. These 
cells, irradiated at 5, 10, or 30 Gy, showed no significant loss of 
viability, consistent with their non-proliferative state (data not shown). 
However, the astrocyte cultures developed mitochondrial 
abnormalities, particularly at the higher radiation doses. These 
abnormalities included decreased ATP levels and increased 
mitochondrial mass per cell (Fig 3), both known consequences of 
mitochondrial impairment. The irradiated astrocytes also developed 
changes in respiratory chain activities, namely decreases in complex II 
and III and, atypical of other forms of mitochondrial toxicity, an 
increase in complex I (Fig 4). Generally, these changes began to 
appear 1 day post-irradiation, persisting for at least 7 days (data not 
shown). When given to the cells immediately after 30 Gy irradiation, 
the salen Mn complex EUK-134 attenuated, in a dose-dependent 
manner, radiation-induced effects on respiratory complex activities 
(Fig 4). This “mito-protection” was significant even when EUK-134 (50 
μM) was added to cultures up to 12 hr after irradiation (30 Gy) (Fig 5). 
These data provide direct evidence for radiation-induced nonlethal 
mitochondrial abnormalities in astrocytes, potentially sufficient to 
cause sustained ROS production and other injurious effects. 
Furthermore, these data support the use of “mito-protective” salen Mn 
complexes to mitigate such injury. Whether these findings extend to 
key target cells for delayed radiation injury in other tissues remains to 
be investigated. However, Vorotnikova et al. [42] showed that several 
compounds with SOD and catalase activities, including the salen Mn 
complexes EUK-189 and EUK-207, inhibited radiation-induced 
apoptosis in bovine adrenal capillary endothelial cell cultures. While 
the mechanism of such anti-apoptosis is not well understood, previous 
findings have shown that staurosporine induced apoptosis, also 
inhibited by salen Mn complexes, is mediated by oxidative stress [43]. 
More recently, EUK-207 was found to prevent several radiation-
induced injuries in human microvascular endothelial cell cultures [44]. 
These findings may be relevant to the potentially broad applicability of 
these agents as radiation mitigators, since the vascular endothelial cell 
is regarded as being an important target for radiation injury in several 
normal tissues [45].  
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Animal Models 
Pulmonary radiation injury - The lung is one of the most susceptible 
organs to potentially debilitating radiation injury. The functional effects 
of pulmonary radiation injury are normally separated into two phases. 
Radiation pneumonitis generally occurs within 2 to 4 months and 
fibrosis tends to develop 4 to 6 months after irradiation [46]. Acute 
pneumonitis is treated with steroids, but can be life-threatening even 
with treatment. Lung fibrosis is permanent and progressive and can 
ultimately lead to respiratory distress, pulmonary hypertension, right 
heart failure and even death. Though the mechanisms are not well 
understood, extensive data suggest that pneumonitis and fibrosis may 
result from a cycle of chronic inflammation and oxidative damage 
initiated by radiation exposure to the lung [4, 7, 47, 48]. 
In Sprague-Dawley rats subjected to partial lung irradiation, 
EUK-189 given by a single subcutaneous (sc) injection suppressed 
micronucleus formation, an indicator of DNA damage in lung 
fibroblasts, measured 18 hr later [49]. This suppression of micronuclei 
counts did not persist without subsequent EUK-189 injections, but it 
was observed even if the EUK-189 injection was delayed until two 
weeks after irradiation. These findings were consistent with 
micronucleus formation resulting from an ongoing cycle of injury and 
repair, consistent with (as discussed above) a continuous “cascade” of 
ROS formation after irradiation. This theory also implies that sustained 
treatment with an ROS scavenger such as a salen Mn complex, would 
be required in order to have a significant impact on lung injury. Thus, 
despite an intriguing report that a single injection of EUK-189 
enhanced hematopoietic survival in lethally irradiated mice [50], the 
single injections of EUK-189, regardless of timing, did not have a 
substantial effect on the clinical outcome of radiation lung injury in the 
rats [49]. Similarly, in a mouse CNS radiation injury model, a single 
injection of EUK-134 failed to show radioprotective efficacy in 
preventing loss of proliferating neuronal precursors [51]. 
Consequently, most subsequent studies with salen Mn complexes have 
increased drug exposure through longer periods of therapy, either by 
daily sc injection or by continuous sc infusion utilizing Alzet osmotic 
pumps. 
One such study [52], also in Sprague-Dawley rats, utilized the 
newer generation compound EUK-207, given by continuous sc infusion. 
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Rats received 10 Gy thoracic irradiation and were monitored for 
indicators of lung injury for 28 weeks, with animals sacrificed for tissue 
collection at various time points (0, 4, 8 and 28 weeks). They received 
EUK-207 (~8 mg/kg-day continuous sc infusion) for 14 wks, beginning 
1 hr after irradiation. As shown in Fig 6, compared to the unirradiated 
controls, irradiated rats showed an increase in breathing rate, 
essentially consisting of two rises, and persisting throughout the 
analysis period. EUK-207-treated irradiated rats, in contrast, showed 
normalized breathing rates. It was of interest that the normalization of 
breathing rate persisted until at least 28 wks, even though drug 
treatment stopped at 14 wks. A well-established biochemical indicator 
of DNA damage due to oxidative stress, the oxidized nucleic acid 8-
OHdG, was significantly higher in lungs from irradiated, versus 
unirradiated, rats at all time points (Fig 7). EUK-207 treated irradiated 
rats showed substantially lower 8-OHdG levels, relative to irradiated 
control rats, indicating suppression of DNA damage due to oxidative 
injury. It was also noted that even unirradiated controls showed a 
slight increase in 8-OHdG over time, perhaps due to some age-related 
changes. As an indicator of lung fibrosis, collagen levels were 
monitored in lung tissue using Masson Trichrome stain imaging (not 
shown) and hydroxyproline content (Fig 8). As the figure shows, lungs 
from untreated irradiated rats had greatly increased hydroxyproline 
levels at 28 wks, and the levels were significantly reduced by EUK-207 
treatment. Similar results were obtained with Masson Trichrome 
staining [52]. Interestingly, and of possible relevance to an anti-
fibrotic effect, the lungs from EUK-207 treated irradiated rats also had 
significantly lower TGF-beta levels, comparable to those of 
unirradiated rats, at 28 wks [52]. The ED-1 stain for activated 
macrophages was also significantly decreased by treatment of EUK-
207 compared to the elevated level of ED-1 stain in irradiated rats 
only. The effects of drug treatment on other cytokines (IL-1 alpha and 
beta, IL-6, and TNF-alpha) were less marked, though there were some 
decreases [52]. Along with EUK-207, Mahmood and colleagues also 
tested the effects of a diet of genistein, a soy isoflavone with 
antioxidant and anti-inflammatory properties, and combined genistein 
with EUK-207 in a third treatment group. Although there were slight 
differences among them, all treatment groups showed similar effects 
on lung injury and oxidative stress parameters [52]. Thus, two 
chemically quite different agents, hypothesized to have similar 
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mechanisms of action, showed significant mitigating effects against 
radiation injury to the lung.  
In another type of rat model for radiation pneumonitis, 
WAG/RijCmcr rats were exposed to 11Gy total body irradiation (TBI) 
followed by syngeneic bone marrow transplant (BMT). This protocol 
avoids death caused by hematopoietic injury. Under such conditions, 
the animals develop pneumonitis by 6 weeks post-irradiation and 
those surviving the lung injury go on to develop radiation-induced 
renal injury, as discussed further in the following section. When this 
strain of rats is exposed to whole thoracic radiation, the resulting 
pulmonary injury is indicated by increased breathing rate, right 
ventricular hypertrophy, increased pulmonary vascular resistance and 
other vascular abnormalities [53, 54]. This radiation-induced 
pneumonitis is mitigated by the angiotensin converting enzyme (ACE) 
inhibitor captopril [55]. Using the TBI/BMT protocol, a combination 
therapy of a suboptimal dose of captopril (100 mg/m2/day) and EUK-
207 (1.8 mg/m2/day), starting 7–10 days post irradiation and 
continuing for 8 weeks, showed promise in mitigating radiation-
induced pneumonitis [56]. The radiation- induced increase in right 
ventricular hypertrophy and pulmonary vascular resistance were 
decreased by EUK-207 and captopril, either alone or in combination 
[57]. In addition, while isolated perfused lungs from irradiated rats 
exhibit lower ACE activity than sham (unirradiated) controls, this 
radiation-induced drop in ACE activity was prevented by EUK-207 (Fig 
9). As shown previously using whole thoracic irradiation protocols, ACE 
activity measured in perfused lungs is lower after irradiation, 
suggesting a decrease in the number of endothelial cells or an 
endothelial cell dysfunction [53, 58]. The finding that EUK-207 therapy 
prevents the loss of ACE activity is consistent with a preservation of 
functional vasculature in the irradiated rats, perhaps via prevention of 
endothelial cell loss. Consistent with this hypothesis, Ghosh et al. [53] 
demonstrated, using imaging techniques, substantial loss of vessel 
density in irradiated lungs. Other options such as a direct induction of 
ACE expression by EUK-207 are, in addition, possible. 
 Similar to the findings in rats, EUK-207 has mitigating effects in 
mouse models for radiation lung injury. Williams et al [59] have 
developed mouse models in which C57BL/6J or CH3/HeJ mice receive 
5Gy to total body followed by 10Gy to lung only. This method causes 
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lethal lung injury while minimizing death due to hematopoietic injury. 
The response of these two strains to radiation is being studied by 
monitoring indicators of pulmonary injury and plasma cytokine levels 
for up to 15 months. When administered by daily sc injection using an 
acute (days 1 to 7 post-irradiation) or chronic (from wk 8 to 26) 
administration, EUK-207 (30 mg/kg-day) improved survival in both 
strains of mouse, especially when co-administered with simvastatin. 
Survival was associated with a decrease in inflammatory infiltration 
and down-regulation of the proinflammatory cytokines IL-1-beta and 
MCP-1 [59]. 
Renal radiation injury - Months to several years after undergoing 
bone marrow transplant requiring TBI, some patients develop renal 
failure and there is considerable evidence that irradiation plays a 
causal role [60]. As discussed above, a TBI/BMT protocol induces 
radiation nephropathy in WAG/RijCmcr rats that is delayed in onset by 
weeks to months. Loss of renal function in this model is indicated by 
the primary clinical endpoints including azotemia (measured as 
increased Blood Urea Nitrogen, BUN), proteinuria (and the urine 
protein to creatinine ratio, UP/UC), and hypertension. Moulder and 
colleagues have reported that captopril and other modulators of the 
renin-angiotensin system mitigate renal injury [61, 62], while a variety 
of other agents, including several antioxidants [63] are ineffective. 
Despite the lack of effect of other antioxidant approaches, including a 
genistein diet [63], several experiments were conducted to evaluate 
salen Mn complexes as potential mitigators in the rat renal injury 
model [64]. 
In the first series of experiments, the compounds were 
administered by continuous sc infusion; therapy was for 12 wks, 
beginning 3 wks after irradiation, with Alzet osmotic pumps delivering 
a constant volume, resulting in a dose of 8 to 10 mg/kg-day. The first 
experiment tested only EUK-189, and it was found to have no 
significant mitigating effect, consistent with what was seen with other 
antioxidant approaches in the radiation nephropathy model [63]. A 
second experiment compared EUK-189 and EUK-207. As shown in Fig 
10, EUK-207 mitigated renal injury caused by 9 Gy TBI, while, again, 
EUK-189 had no significant effect. It is interesting to note that this 
mitigation was observed 26 wk after irradiation, 11 wks after drug 
treatment had ended. In a third experiment, employing 10 Gy TBI to 
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accelerate renal injury, EUK-207 was compared to captopril, the latter 
given orally in the drinking water (12 to 15 mg/kg-day), in the same 
schedule as that used for EUK-207. As shown in Fig 11, mitigation by 
EUK-207 was comparable to that of captopril when measured at 13 
wks, though with a lesser degree of effectiveness at 17 wks, 2 wks 
after termination of drug therapy. 
 As discussed above, captopril and other agents acting on the 
renin-angiotensin system are regarded as the “gold standards” for 
mitigating radiation-induced renal injury, whereas a variety of other 
antioxidant agents have shown no benefit. Thus, the activity of EUK-
207 in the kidney is of particular interest, as is the lack of effect of 
EUK-189. This finding differs from those in a mouse age-associated 
cognitive impairment model, in which EUK-189 and EUK-207 showed 
comparable efficacy, including dose-dependency [21]. Perhaps in the 
renal model the greater plasma half-life of EUK-207, versus that of 
EUK-189 (Fig. 2), is important for mitigating renal injury, supporting a 
vascular site of action for the compounds in the radiation nephropathy 
model. It was noted during the sc infusion studies that the dose of 
EUK-207 employed in the pumps caused a skin reaction in a subset of 
irradiated rats, in some cases requiring pump removal. Lower doses 
(about 2 mg/kg-day) were found to be ineffective in mitigating 
radiation nephropathy. This is contrast to the lung and skin models in 
the same strain of rats, where this lower dose range of EUK-207 did 
cause substantial mitigation of radiation injury. 
To test an alternative method of delivery to the infusion pumps, 
an experiment was conducted using sc daily injections of EUK-207, 
beginning 48 hr after irradiation and continuing for 10 wks. As shown 
in Table 2, EUK-207 at 30 mg/kg per day showed significant mitigating 
activity, whereas lower doses did not. The effective dose of EUK-207, 
although well tolerated in other rodent models, also caused localized 
skin reaction hindering its repeated injection at the same site. 
Apparently, the compromised skin in TBI-treated WAG/RijCmcr rats is 
vulnerable to this reaction, the mechanism of which is not yet 
understood. In another study similar to that described in Table 2, EUK-
207 was combined with captopril at sub-optimal doses (10 mg/kg-day 
sc and 150 mg/l in drinking water, respectively). The combination 
showed no more activity than the captopril alone, suggesting a lack of 
additivity or synergy between the two treatments. Such data suggest 
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that the lower dose of EUK-207 given by daily injection, 10 mg/kg-
day, is ineffective. Nonetheless, the higher dose (30 mg/kg-day sc 
injected or 8–10 mg/kg-day by continuous sc infusion) does have 
substantial mitigating activity in the renal injury model. 
 However, efficacy of salen Mn complexes would not necessarily 
have been predicted because the mechanism of renal injury in this 
model, particularly the involvement of oxidative stress, is in question. 
A study examining several indicators of oxidative injury, including 8-
OHdG and protein carbonyl, failed to find evidence for increased 
oxidative stress in irradiated, versus unirradiated rats in this TBI/BMT 
model [65]. As the authors concluded, “if chronic oxidative stress is 
part of the pathogenesis of radiation nephropathy, it does not leave 
widespread or easily detectable evidence behind”. Results in the 
radiation nephropathy model contrast with those in the radiation-
induced pulmonary injury model [52], where there was a clear 
increase in 8OHdG levels in lungs from irradiated rats, and a 
substantial decrease with EUK-207 treatment. In addition, as noted 
above, EUK-207 and genistein had comparable effects in the lung 
injury model [52], whereas genistein and several other antioxidants 
were ineffective in the renal model [63]. Such observations, while not 
excluding its involvement, bring into question the importance of 
oxidative stress, and its mitigation, in the renal injury model. The 
mitigating effects of EUK-207 might involve another mechanism 
altogether but, in any event, EUK-207 was not as effective as captopril 
in this model. Further supporting its use as a mitigator of radiation 
renal injury, captopril is an FDA-approved drug that has been used 
widely as an antihypertensive, and its safety has been established in 
patients undergoing TBI in preparation for bone marrow 
transplantation [66]. While EUK-207 may also be of therapeutic use to 
mitigate renal radiation injury, its use as an adjunct or alternative 
therapy to captopril is not, to date, well-supported by the rodent 
model data. 
Oral mucosa - Oral mucositis is a dose-limiting toxicity in patients 
receiving chemotherapy or localized radiation treatment for head and 
neck cancers [67, 68]. ROS have been an interventional target for the 
prevention and treatment of mucositis, with N-acetylcysteine as one 
agent under study. The ability of EUK-189 to mitigate radiation-
induced mucositis was tested in a hamster model, performed as 
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described previously [69]. EUK-189, as compared to EUK-207, is 
particularly attractive as a topically administered agent because of its 
greater lipophilicity (Table 1) as well as its shorter plasma half-life 
(Fig. 2). The latter property should help to minimize any unwanted 
systemic effects in an agent intended to act locally. Briefly, the cheek 
pouches of anesthetized hamsters were everted to expose the oral 
mucosa and the surface was irradiated with a single exposure of 35 
Gy. This resulted in severe to moderate oral mucositis by 15 days. 
EUK-189 was administered by two methods in this study. One was a 
daily sc injection (30 mg/kg), given immediately after irradiation and 
each day thereafter, through day 14 (with day 0 being the day of 
irradiation). A second method utilized topical administration. EUK-189 
solutions in water, at three different concentrations (3.3, 10 and 30 
mg/ml) were applied four times on each day (from day 0 til 14) in the 
following manner: one observed application, where 0.2 ml EUK-189 
solution was applied directly to the mucosa of an anesthetized 
hamster; three blind applications, where 0.3 ml of EUK-189 solution 
was delivered into the cheek pouch of the conscious animal. Vehicle 
(water) was administered to control groups in an analogous manner. 
Exposed buccal pouches were photographed on alternate days, 
beginning at day 6 and photographs scored blindly for mucositis 
severity, as described [69]. Using this standard 6-point severity score, 
a score of greater than 3 in this animal model corresponds to National 
Cancer Institute or WHO clinical scores of ≥3 [69], indicating a 
clinically significant ulcerative mucositis. Consequently, the data are 
presented as the prevalance of a mucositis score of ≥3 [69]. As shown 
in Fig 12, both methods of EUK-189 administration resulted in a 
significant decrease in mucositis severity. With the topical 
administration protocol, the two higher doses of EUK-189 were 
effective. This protocol was included because it mimics the way the 
drug might be given clinically, with a lozenge or mouth rinse the likely 
formulations for patients. The sc administration was included as a 
“positive control”, since this route of EUK-189 delivery has shown 
efficacy in other pharmacological models. Though some of the “topical” 
EUK-189 rinse was probably also swallowed by the animals, it is not 
likely that this added to its effect, as EUK-189 is not orally bioavailable 
[70]. 
 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
17 
 
 It is interesting to note that the prolonged, 15 day, 
administration of EUK-189 was effective using both dosing protocols. 
In contrast, efficacy in attenuating oral mucositis by the SOD mimetic 
M40403, a Mn macrocyclic complex reported to lack catalase activity 
[71], was dose-schedule dependent in this model [69]. While M40403, 
given by ip injections (30 mg/kg) twice per day, from day -1 to day 3, 
mitigated oral mucositis, the mitigation effect was absent when the 
compound was given from day -1 to day 15. Also, administration of 
M40403 beginning on day 0 was more effective than beginning before 
irradiation (day -1), with a day 0 through 3 dosing having the greatest 
effect. One can speculate on a number of possible explanations for the 
apparent differences in schedule dependence between these two 
compounds. One hypothesis is that excess hydrogen peroxide could 
prolong mucositis by impairing healing, similar to the complex role 
that this ROS is known to play in skin wound healing [72]. Possibly, 
extended dosing with the SOD mimetic M40403 resulted in later 
increases in hydrogen peroxide, whereas EUK-189 scavenges both 
superoxide and hydrogen peroxide. Nonetheless, both mucositis 
studies do support the potential value of both classes of ROS 
scavenging Mn complexes in mitigating radiation-induced oral 
mucositis. Given the commonality in underlying pathogenesis [69], it 
is also likely that both compounds would also be efficacious in 
attenuating chemotherapy-induced mucositis. 
Cutaneous radiation injury - Radiation dermatitis is a consequence 
of radiation therapy, for example in breast and lung cancer patients, 
and cutaneous radiation exposure can impair wound healing. The 
cutaneous injury after radiation exposure involves a combination of 
inflammatory processes and alteration of cellular proliferation involving 
release of pro-inflammatory cytokines, growth factors, and adhesion 
molecules [73]. Furthermore, fibrinogenesis and angiogenesis are 
directly inhibited by ionizing radiation. Previous studies indicate that 
ionizing radiation causes fibroblasts to show reduced proliferation, 
atypical migration, and abnormalities in collagen synthesis [74, 75]. 
Several studies reported changes in the extracellular matrix 
composition after radiation injury affecting the healing time of 
wounded skin [76, 77]. Moreover, a growing body of evidence 
supports a causative role of oxidative stress in the development of 
cutaneous radiation syndrome and delayed healing response following 
radiation exposure [3, 7]. Such data imply that salen Mn complexes 
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could have beneficial effects in models for cutaneous radiation injury. 
Thus, EUK-207 was tested in a rat model for combined radiation 
dermatitis and skin wound healing [78–80]. In this model, 
WAG/RijCmcr rats were irradiated dorso-ventral with a 15kVp soft x-
ray beam that has a steep dose gradient, a protocol enabling delivery 
of high doses (10 to 40 Gy, defined at the upper dermis) to the skin 
without significant exposure to internal organs. Rats received full 
thickness wounds by punch biopsy within one hour of irradiation. 
Dermatitis was scored weekly using a semi-quantitative scoring 
system for skin injury [81] and wound closure was monitored by 
image analysis of traced wound areas. Irradiated rats developed, in a 
radiation dose-dependent manner, cutaneous radiation reactions 
ranging in severity from transient erythema (onset 24 hours, duration 
1–2 days) to large deep scabs and non-healing ulcers (onset day 21, 
duration up to 90 days), plus alopecia (onset day 20, duration up to 90 
days) and skin fibrosis (onset day 30, duration entire period of study). 
There was markedly impaired wound healing, also dependent on 
radiation dose. The peak of acute skin reactions was ~ 30 days. As 
reported [78–80]. a number of other assessments demonstrated 
radiation-induced changes in extracellular matrix deposition, blood 
vessel proliferation, gene expression changes and oxidative stress 
indicators in the skin. 
EUK-207 was evaluated in this cutaneous combined injury 
model, using the 30 Gy radiation dose that, without drug treatment, 
induced severe cutaneous injury and wounds that failed to heal over 
the 90 day observation period. EUK-207 (~1.8 mg/kg-day) or vehicle 
(water) were given by sc Alzet infusion pumps beginning 48 hr after 
irradiation and continuing for up to 90 days. As reported [78, 80], 
there was a dramatic mitigation effect of EUK-207 on radiation injury, 
including improvement of wound healing. Within one month, EUK-207 
treated rats had reduced moist desquamation, reduced tissue 
inflammation, and increased wound contraction. Unlike the vehicle 
treated groups, those treated with EUK-207 showed only slight tissue 
fibrosis at 90 days post-irradiation, and interestingly, there was even 
growth of new hair within the center of the radiation field. Also unlike 
the vehicle treated animals, those in the EUK-207 treatment groups 
had wounds that were fully healed. 
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While, based on its other in vivo effects, the mitigation of 
radiation dermatitis by EUK-207 was not unexpected, the beneficial 
effect of an ROS scavenger on wound healing in this combined-injury 
scenario would not necessarily have been predicted. ROS, particularly 
hydrogen peroxide, have been reported to play key signaling roles to 
promote wound healing, and localized transfection of catalase delays 
healing in rodents [72, 82]. Yet, in other experiments, excess 
hydrogen peroxide impaired healing [72] and transfection with sod2 
improved wound healing [83] as did chronic administration of a 
mitochondrially targeted antioxidant to aged mice [84]. Thus, the role 
of ROS, particularly hydrogen peroxide, and of redox regulation in 
cutaneous wound healing is highly complex. Despite this, our study 
and others support the notion that selected ROS-scavenging agents 
such as EUK-207, given under the right circumstances, can mitigate 
radiation-induced skin injury, including facilitating wound healing. 
IV. Future directions and challenges 
Drug delivery methods 
As discussed in this review, salen Mn complexes, especially 
EUK-207, mitigate radiation injury to a number of normal tissues. One 
important issue to be addressed in their further development as 
mitigating agents is the method of drug delivery. Evidence indicates 
that systemic use for a number of days, or even weeks, may be 
needed for optimal effectiveness. With the chronic, continuous nature 
of the oxidative stress that is implicated in delayed radiation injury 
[7], this is not at all surprising. It is promising, however, that 
mitigating effects of EUK-207 in pulmonary and renal models persist 
weeks after drug therapy has ended. Currently, daily injection and 
continuous sc infusion are the most effective means of delivery for 
salen Mn complexes. Such methods of delivery, even portable infusion 
pumps such as those delivering insulin, are tolerated by patients for 
certain chronic diseases, but are not the most desirable. Oral 
administration, instead, would be very convenient for some of these 
indications. Salen Mn complexes, even EUK-207 which has high 
stability to gastric solutions (Table 1), are not orally available in 
rodents [70]. We [70, 85] and others [86] have described low 
molecular weight uncharged Mn porphyrins which have ROS 
scavenging properties and also can be orally delivered to rodents. The 
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series that we have studied, in particular compounds known as EUK-
418, EUK-423 and EUK-451, are, like EUK-189 and EUK-207, anti-
apoptotic in a PC12 cell culture system [70] and mitigate apoptosis of 
capillary endothelial cell cultures induced by ionizing radiation [42]. 
While such studies suggest that these “EUK-400 series” compounds 
may be promising for mitigation of radiation injury in vivo they are, as 
a class, more cytotoxic than EUK-189 and EUK-207. Their efficacy in 
both cell culture systems was limited by their toxicity, with EUK-451 
being the most effective Mn porphyrin and the least toxic. But the 
salen Mn complexes EUK-189 and EUK-207 were even less toxic, 
displaying no cytotoxicity at any of the doses tested. Of course, an 
increased toxicity would be tolerable if the compound were 
substantially more potent, but these Mn porphyrins were only slightly 
more (about 3-fold) potent than salen Mn complexes in the cellular 
models [42, 70]. In a preliminary in vivo study, EUK-451, 
administered to WAG/RijCmcr rats via drinking water and, as a 
positive control, by sc osmotic infusion pumps, did not mitigate 
radiation renal injury (Fish, Moulder et al., unpublished data). 
However, studies to optimize dosing and pharmacokinetics remain to 
be conducted. In addition, the renal injury model, in which, as 
discussed above, very few agents show any mitigating activity and the 
role of oxidative stress is questionable, is not necessarily the best 
choice for testing an unknown agent hypothesized to act as an ROS 
scavenger. An orally available Mn porphyrin developed by another 
group [87] does show neuroprotective efficacy in a rodent Parkinson’s 
disease model [86] suggesting that the approach of investigating low 
molecular weight Mn porphyrins still has the potential to lead to 
interesting orally bioavailable therapeutic agents. For further 
discussion of Mn porphyrins, other chapters in this volume review the 
use of this class of Mn-ligand complex to mitigate radiation injury, 
including compounds that, like salen Mn complexes, are given by 
injection or infusion. For example, a catalytic Mn porphyrin ROS 
scavenger known as AEOL 10150 mitigates lung injury caused by 
thoracic irradiation in the rat when given by continuous sc infusion 
[88, 89]. 
For some normal tissue radiation mitigation indications, a topical 
means of delivering salen Mn complexes, if effective, would be 
therapeutically practical. Some data with these compounds are 
promising in this regard. In the hamster mucositis model, a topical 
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dosing regimen, consisting of direct application of EUK-189 to the 
cheek pouch mucosa, showed efficacy equivalent to that of sc 
injection. In patients, a lozenge or mouth rinse could be useful to 
mitigate oral mucositis. In the cutaneous injury studies described here, 
only systemic EUK-207 was tested. However, EUK-189 and EUK-207 
can be formulated into a topical preparation that reduces ear 
inflammation in the mouse (Doctrow et al., unpublished data). 
Furthermore, topical application of an EUK-134 preparation to the skin 
of human volunteers was shown to prevent skin lipid peroxidation 
caused by UVA exposure [90]. Such data support the future testing of 
topical preparations of salen Mn complexes to mitigate cutaneous 
radiation injury. Inhaled methods of EUK-207 delivery are also under 
investigation, especially for pulmonary radiation injury (Williams, 
Finkelstein, Doctrow and colleagues). 
Mechanism of action: role of ROS scavenging in 
mitigation 
As discussed throughout this review, the mechanisms of action 
of salen Mn complexes, as with any other mitigator of delayed 
radiation injury, are likely to be complex. Increased understanding of 
these mechanisms could help in future development of analogs, as well 
as improved drug delivery and dosing protocols, optimized for each 
specific radiation injury indication. Data in astrocyte cultures support 
the hypothesis that the compounds’ “mito-protective” properties are 
relevant to delayed radiation injury, though this should be further 
studied in other cell types as well as in vivo. Findings in certain models 
support the hypothesis that salen Mn complexes are acting as ROS 
scavengers in vivo. For example, in one rat lung injury model [52], 
EUK-207 treatment mitigated signs of pneumonitis and fibrosis, while 
concomitantly decreasing lung levels of oxidized nucleic acid. Similar 
mitigation of oxidative-stress associated markers was reported in the 
cutaneous injury model [78, 80]. While such associations do not prove 
causality they are promising indicators that the ROS scavenging 
properties of these agents measured in vitro extend to an ability to 
mitigate oxidative stress in vivo. In the renal injury model, however, 
the role of oxidative stress is in question [63, 65]; and EUK-207 
mitigated renal injury, while numerous antioxidant agents, including 
EUK-189, did not. Therefore, for the renal injury model, other 
mechanisms, including some hypothetical modulation of the renin-
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angiotensin system, should be addressed in future research. More 
generally, however, it seems likely that combined therapies using two 
or more agents with distinct mechanisms of action are likely to be 
more effective than one agent alone for a complex indication such as 
delayed radiation injury [59]. 
The pro-oxidative effects of redox cycling agents, including ROS 
scavenging compounds, can potentially cause toxicities or confound 
understanding of the mechanism of action in biological systems [6]. 
Any ability of an ROS scavenger to also generate ROS might be 
regarded as a “pro-oxidative” activity. As discussed elsewhere in this 
review, the ability of a “pure” SOD mimetic, or the enzyme SOD, to 
generate hydrogen peroxide can potentially cause damaging effects. In 
an intestinal cell culture model, EUK-8 had a protective effect against 
injury caused by acidosis, whereas bovine CuZnSOD alone 
exacerbated injury, an effect that was reversed by the addition of 
bovine catalase [91]. In general, while pro-oxidative effects of salen 
Mn complexes have not been ruled out in all biological contexts, the 
toxicity of some analogs in cell culture is not associated with their 
inherent catalytic properties but, instead, with other parameters such 
as instability and release of toxic metabolites of the ligand [5]. In a 
wide range of in vivo models, as reviewed earlier, salen Mn complexes 
decrease, rather than increase, biochemical indicators of oxidative 
stress such as oxidized nucleic acids and protein tyrosine nitration. 
While they suppress signals of ROS “probes” in many instances, under 
some conditions salen Mn complexes cause increased fluorescence of 
the commonly used “ROS-indicator” dye dichlorofluoroscein (DCF) [51, 
92]. This does not appear to be an ROS-generating effect. Instead, 
this effect is likely due to the peroxidase activity of salen Mn 
complexes, that is, their ability to catalyze oxidation of substrates in 
the presence of hydrogen peroxide. Peroxidase enzymes are among 
the arsenal of endogenous antioxidant defenses [6] and peroxidase 
activity is an inherent component of the hydrogen peroxide scavenging 
mechanisms of salen Mn complexes [5], Mn porphryins [93], and 
mammalian catalase enzymes [94]. Though it can be oxidized by other 
ROS, DCF is considered to be an intracellular “ROS indicator” primarily 
because it is an oxidizable substrate whose fluorescence is increased 
by endogenous cellular peroxidases acting in the presence of hydrogen 
peroxide [6]. In cultured rat neural progenitor cells, Limoli et al [51] 
found that EUK-189 caused an increased DCF fluorescence in either 
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irradiated or unirradiated cells. This experiment was repeated with two 
other salen Mn complexes having comparable SOD activities; EUK-172, 
an analog with a high catalase/peroxidase activity, stimulated DCF 
fluorescence, while EUK-163, with no significant catalase/peroxidase 
activity, did not. If generation of hydrogen peroxide had been the 
reason for increased DCF fluorescence, EUK-163, with SOD but no 
catalase activity, would have been expected to cause higher, not 
lower, fluorescence than EUK-172. This observation supported the 
hypothesis that salen Mn complexes can act as functional peroxidases 
inside cells acting on oxidizable substrates such as DCF. Essentially, 
the compounds are metabolizing, rather than generating, hydrogen 
peroxide in the process and, therefore, are not behaving as “pro-
oxidative” agents. Such observations also illustrate the need to 
understand the potential artifacts associated with any fluorescent 
probe when using it as an indicator substance. 
Reaching sites of action: lipophilicity, stability and other 
properties 
The cellular or subcellular target for a given form of radiation 
injury should have considerable influence on the properties required of 
a mitigator. As discussed throughout this review, potential cellular and 
subcellular sites of action include the vascular endothelial cell and the 
mitochondria, respectively. An extravascular site of action, if needed 
for a given indication, would require the agent to transit the vascular 
wall and permeate tissues. Efforts to improve biological efficacy of 
salen Mn complexes have included increasing lipophilicity which should 
enhance delivery into cells and across vascular barriers. As a class, 
salen Mn complexes are more hydrophilic than lipophilic, though a 
modest increase in lipophilicity has been found to increase their 
effectiveness in certain experimental models. For example, EUK-189, 
while having the same ROS scavenging activities as EUK-134, is more 
lipophilic, due to its having ethyoxy rather than methoxy side chains 
[5]. This increased lipophilicity is hypothesized to explain why EUK-
189 is more potent than EUK-134 at preventing neuronal apoptosis 
[43] and is more effective as a “mito-protector” in sod2−/− mice [26]. 
Yet, lipophilicity alone does not determine effectiveness. For example, 
EUK-207 which, as discussed above, is more stable than EUK-189 and 
is also considerably less lipophilic (Table 1) [17, 70]. Both compounds 
showed equivalent potency and efficacy in an age-related cognitive 
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impairment model [18, 21], and it was suggested that the decreased 
lipophilicity of EUK-207, relative to that of EUK-189, was balanced by 
its increased intracellular stability. Indeed, in cell culture studies, EUK-
207 is more potent than EUK-189 in suppressing apoptosis [70], an 
intracellular injury, while having similar potency against extracellularly 
generated hydrogen peroxide (Doctrow et al., unpublished data), in a 
model in which catalase activity of a compound is related to its 
cytoprotective activity [5]. Attempts to increase the lipophilicity of 
cyclized salen manganese complexes have included EUK-207 analogs 
with aromatic bridge structures [20] or 5,5′-alkoxy substituents 
(Doctrow et al., unpublished). Such compounds were not appreciably 
more effective than EUK-207 in cellular models and, in some cases, 
were more toxic. The orally available “EUK-400 series” compounds 
were, for the most part, substantially more lipophilic than the salen Mn 
complexes to which they were compared. However, the most 
cytoprotective, least toxic Mn porphyrin, EUK-451, was the least 
lipophilic, with a negative logP value (Table 1), more similar to those 
of the salen Mn complexes than to the other “EUK-400 series” 
compounds [70]. While not conclusive, such observations do suggest 
that too much lipophilicity, besides making an agent difficult to 
formulate, could have toxicology implications. Overall, several factors 
such as lipophilicity, inherent stability, potential toxicity and, of course, 
in vivo efficacy must be weighed against one another in selecting a 
lead compound. The preponderance of data, in vitro as well as in vivo, 
indicates that EUK-207 exhibits a number of properties that justify its 
selection as a lead salen Mn complex. 
Safety and tolerability 
As with any class of therapeutic agent, the safety and 
tolerability of salen Mn complexes must be determined in the course of 
a normal drug development program. To date, salen Mn complexes 
have not undergone formal clinical testing. Salen Mn complexes, as 
noted above, are substantially less cytotoxic than Mn porphyrins such 
as the “EUK-400 series” compounds [70]. They are also well tolerated 
in chronic administration, for example, EUK-189 and EUK-207 were 
given to aged mice by continuous infusion for up to 6 months with no 
adverse effects noted [21]. The original prototype EUK-8 was given to 
mice by repeated injections (30 mg/kg ip, 3 times per wk) for 24 wks 
with no discernable impact on mortality, body weight or gross 
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pathology assessment [16]. As discussed above [42, 70], EUK-189 
and EUK-207 displayed no cytotoxicity under conditions where the 
“EUK-400 series” of Mn porphyrins did. Among a series of salen Mn 
complexes, those analogs that did exhibit toxicity in cell culture and in 
vivo included those that were less stable, apparently releasing toxic 
metabolites [5]. The renal injury model studies, however, do indicate 
that EUK-207 can cause localized reactions at high doses in irradiated 
skin, though this might not occur in other strains or species and other 
methods of delivery, even other formulations, might overcome this 
issue. 
The role of the metal in a metal-ligand complex 
The presence of a metal, even one such as Mn that is normally 
present in vivo, would be a potential toxicity concern for any agent, 
and would need to be addressed. Indeed, toxicity issues aside, the role 
of free metal, either as a contaminant [95], transferred by a metal-
metal exchange or released via metabolism of the complexes, in the 
biological effects of any synthetic metal ligand complex is also an issue 
relevant to its mechanism(s) of action. In the case of salen Mn 
complexes, structure-activity relationship studies showed that Mn 
acetate salts had no catalase activity or cytoprotective properties, 
though they show SOD activity [5]. It is also of note that, among salen 
Mn complexes, more stable metal-ligand complexes show greater 
potency in cytoprotective assays, for example, EUK-207 is effective at 
lower doses than EUK-189 at preventing apoptosis, while the two 
compounds have similar catalytic properties [70] and essentially 
equivalent potency at protecting cells against extracellular hydrogen 
peroxide, where, unlike the apoptosis assay, intracellular stability of 
the salen Mn complex is not a factor (Doctrow et al., unpublished 
data). Other analytical controls, such as ESI-MS, chelator incubation 
studies [70, 95] and catalytic activity analysis of HPLC peaks 
corresponding to the intact metal-ligand complex can provide evidence 
that free metal contaminants are either not detectable, or are not 
responsible for biological properties of interest in vitro [70]. However, 
such control experiments cannot rule out the possibility, which exists 
for any therapeutically investigated metal-ligand complex, that the 
drug functions in part by delivering active metal to some site of action. 
Indeed, effective delivery of Mn could very well be a component of the 
in vivo mechanism of action of salen Mn complexes, Mn porphryins, 
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and other biologically active metal ligand complexes. Though such 
complex mechanistic questions are difficult to address, future research 
in the field might help to illuminate them. More broadly, because of 
the interesting, potentially promising biological activities of metals as 
components of inorganic complexes, the field of “Metals in Medicine”, 
or medicinal inorganic chemistry, is of growing importance [96, 97]. At 
least three other classes of Mn-containing compounds have undergone 
clinical testing, either as diagnostic imaging agents [98] or 
experimental therapeutics [99, 100]. This should help to pave the way 
for developing new classes of Mn-based therapeutic agents such as 
salen Mn complexes. 
V. Conclusion 
Synthetic SOD/catalase mimetics, particularly the salen Mn 
complexes exemplified by EUK-189 and EUK-207, mitigate radiation 
injury to normal tissues, including lung, kidney, skin and oral mucosa. 
These findings indicate that these agents could have potential value as 
adjunct therapies following radiation therapy. Future development of 
salen Mn complexes should focus on optimizing their methods of 
delivery and increasing an understanding of their mechanisms of 
action and potential side effects. 
Acknowledgments 
Development of the salen Mn complexes, including EUK-207, was 
funded in part by GM57770 (SRD). Renal, cutaneous, and pulmonary studies 
and further compound development were supported by AI067734 (JEM), 
including a pilot grant (RAR) to study EUK-400 compounds. Some pulmonary 
studies were also supported by AI81294 (MM). The mucositis study was 
performed by Biomodels, LLC. (Wellesley, MA) under the direction of STS, 
with funding by Eukarion, Inc. The mitochondrial injury studies were 
supported by CA72156 (PJT). 
References 
1. Movsas B, Vikram B, Hauer-Jensen M, Moulder JE, Basch E, Brown SL, 
Kachnic LA, Dicker AP, Coleman CN, Okunieff P. Decreasing the 
Adverse Effects of Cancer Therapy: National Cancer Institute Guidance 
for the Clinical Development of Radiation Injury Mitigators. Clin Cancer 
Res. 17(2):222–228.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
27 
 
2. Greenberger JS, Epperly MW. Radioprotective antioxidant gene therapy: 
potential mechanisms of action. Gene Therapy and Molec Biol. 
2004;8:31–44. 
3. Zhao W, Diz DI, Robbins ME. Oxidative damage pathways in relation to 
normal tissue injury. Br J Radiol. 2007;80(Spec No 1):S23–31.  
4. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in 
radiation-induced late normal tissue injury: therapeutic implications. 
Curr Med Chem. 2009;16(2):130–43.  
5. Doctrow SR, Huffman K, Marcus CB, Tocco G, Malfroy E, Adinolfi CA, Kruk 
H, Baker K, Lazarowych N, Mascarenhas J, Malfroy B. Salen-
manganese complexes as catalytic scavengers of hydrogen peroxide 
and cytoprotective agents: structure-activity relationship studies. J 
Med Chem. 2002;45(20):4549–58.  
6. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 4. 
Oxford University Press; Oxford: 2007.  
7. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late 
normal tissue injury: a review. Int J Radiat Biol. 2004;80(4):251–9.  
8. Jiang J, Stoyanovsky DA, Belikova NA, Tyurina YY, Zhao Q, Tungekar MA, 
Kapralova V, Huang Z, Mintz AH, Greenberger JS, Kagan VE. A 
mitochondria-targeted triphenylphosphonium-conjugated nitroxide 
functions as a radioprotector/mitigator. Radiat Res. 2009;172(6):706–
17.  
9. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target 
and broad-spectrum radioprotector. Oncologist. 2007;12(6):738–47.  
10. Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman 
MC, Spitz DR. Amifostine induces antioxidant enzymatic activities in 
normal tissues and a transplantable tumor that can affect radiation 
response. Int J Radiat Oncol Biol Phys. 2009;73(3):886–96.  
11. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff 
MH, Dynan WS, Fike JR, Grdina DJ, Greenberger JS, Hauer-Jensen M, 
Hill RP, Kolesnick RN, Macvittie TJ, Marks C, McBride WH, Metting N, 
Pellmar T, Purucker M, Robbins ME, Schiestl RH, Seed TM, 
Tomaszewski JE, Travis EL, Wallner PE, Wolpert M, Zaharevitz D. 
Models for evaluating agents intended for the prophylaxis, mitigation 
and treatment of radiation injuries. Radiat Res; Report of an NCI 
Workshop; December 3–4, 2003; 2004. pp. 711–28.  
12. Sharpe MA, Ollosson R, Stewart VC, Clark JB. Oxidation of nitric oxide by 
oxomanganese salen complexes: a new mechanism for cellular 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
28 
 
protection by superoxide dismutase/catalase mimetics. Biochem J. 
2002;366:97–107.  
13. Rong Y, Doctrow SR, Tocco G, Baudry M. EUK-134, a synthetic superoxide 
dismutase and catalase mimetic, prevents oxidative stress and 
attenuates kainate-induced neuropathology. Proc Natl Acad Sci U S A. 
1999;96(17):9897–902.  
14. Pong K, Doctrow SR, Baudry M. Prevention of 1-methyl-4-
phenylpyridinium- and 6-hydroxydopamine-induced nitration of 
tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide 
dismutase and catalase mimetic, in cultured dopaminergic neurons. 
Brain Res. 2000;881(2):182–9.  
15. Doctrow SR, Huffman K, Marcus CB, Musleh W, Bruce A, Baudry M, 
Malfroy B. In: Antioxidants in Disease Mechanisms and Therapeutic 
Strategies. Sies H, editor. Academic Press; New York: 1997. pp. 247–
270. 
16. Doctrow SR, Adinolfi C, Baudry M, Huffman K, Malfroy B, Marcus CB, 
Melov S, Pong K, Rong Y, Smart J, Tocco G. In: Oxidative Stress and 
Aging: Advances in Basic Science, Diagnostics, and Intervention. 
Rodriguez H, Cutler R, editors. World Scientific Publishing Company; 
Singapore, London, NJ: 2003. pp. 1324–1342. 
17. Doctrow SR, Baudry M, Huffman K, Malfroy B, Melov S. In: Medicinal 
Inorganic Chemistry. Sessler SRDJL, McMurry TJ, Lippard SJ, editors. 
American Chemical Society and Oxford University Press; New York: 
2005. pp. 319–347. 
18. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, Baudry M. 
Reversal of age-related learning deficits and brain oxidative stress in 
mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci 
U S A. 2003;100(14):8526–31.  
19. Jung C, Rong Y, Doctrow S, Baudry M, Malfroy B, Xu Z. Synthetic 
superoxide dismutase/catalase mimetics reduce oxidative stress and 
prolong survival in a mouse amyotrophic lateral sclerosis model. 
Neurosci Lett. 2001;304(3):157–60.  
20. Malfroy-Camine B, Doctrow SR. U.S. Patent Number 7,122,537. Cyclic 
salen-manganese compounds: reactive oxygen species scavengers 
useful as antioxidants in the treatment and prevention of diseases. 
2006 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
29 
 
21. Clausen A, Doctrow S, Baudry M. Prevention of cognitive deficits and 
brain oxidative stress with superoxide dismutase/catalase mimetics in 
aged mice. Neurobiol Aging (online 2008) 2010;31:425–33.  
22. Rajagopalan MS, Stone B, Rwigema JC, Salimi U, Epperly MW, Goff J, 
Franicola D, Dixon T, Cao S, Zhang X, Buchholz BM, Bauer AJ, Choi S, 
Bakkenist C, Wang H, Greenberger JS. Intraesophageal manganese 
superoxide dismutase-plasmid liposomes ameliorates novel total-body 
and thoracic radiation sensitivity of NOS1−/− mice. Radiat Res. 
2010;174(3):297–312.  
23. Epperly MW, Epstein CJ, Travis EL, Greenberger JS. Decreased pulmonary 
radiation resistance of manganese superoxide dismutase (MnSOD)-
deficient mice is corrected by human manganese superoxide 
dismutase-Plasmid/Liposome (SOD2-PL) intratracheal gene therapy. 
Radiat Res. 2000;154(4):365–74.  
24. Aykin-Burns N, Slane BG, Liu AT, Owens KM, O’Malley MS, Smith BJ, 
Domann FE, Spitz DR. Sensitivity to Low-Dose/Low-LET Ionizing 
Radiation in Mammalian Cells Harboring Mutations in Succinate 
Dehydrogenase Subunit C is Governed by Mitochondria-Derived 
Reactive Oxygen Species. Radiat Res. 2011;175(2):150–8.  
25. Hinerfeld D, Traini MD, Weinberger RP, Cochran B, Doctrow SR, Harry J, 
Melov S. Endogenous mitochondrial oxidative stress: 
neurodegeneration, proteomic analysis, specific respiratory chain 
defects, and efficacious antioxidant therapy in superoxide dismutase 2 
null mice. J Neurochem. 2004;88(3):657–67.  
26. Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, 
Huffman K, Wallace DC, Malfroy B. Lifespan extension and rescue of 
spongiform encephalopathy in superoxide dismutase 2 nullizygous 
mice treated with superoxide dismutase-catalase mimetics. J Neurosci. 
2001;21(21):8348–53.  
27. Smith RA, Murphy MP. Animal and human studies with the mitochondria-
targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103.  
28. Zhang HJ, Doctrow SR, Xu L, Oberley LW, Beecher B, Morrison J, Oberley 
TD, Kregel KC. Redox modulation of the liver with chronic antioxidant 
enzyme mimetic treatment prevents age-related oxidative damage 
associated with environmental stress. Faseb J. 2004;18(13):1547–9.  
29. Peng J, Stevenson FF, Doctrow SR, Andersen JK. Superoxide 
dismutase/catalase mimetics are neuroprotective against selective 
paraquat-mediated dopaminergic neuron death in the substantial 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
30 
 
nigra: implications for Parkinson disease. J Biol Chem. 
2005;280(32):29194–8.  
30. Zhang HJ, Drake VJ, Xu L, Xie L, Oberley LW, Kregel KC. Heat-induced 
liver injury in old rats is associated with exaggerated oxidative stress 
and altered transcription factor activation. FASEB J. 2003;17:2293–
2295.  
31. Tocco G, Illigens BM, Malfroy B, Benichou G. Prolongation of alloskin graft 
survival by catalytic scavengers of reactive oxygen species. Cell 
Immunol. 2006;241(2):59–65.  
32. Luciani A, Villella VR, Vasaturo A, Giardino I, Raia V, Pettoello-Mantovani 
M, D’Apolito M, Guido S, Leal T, Quaratino S, Maiuri L. SUMOylation of 
tissue transglutaminase as link between oxidative stress and 
inflammation. J Immunol. 2009;183(4):2775–84.  
33. Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M, 
Guido S, Cexus ON, Peake N, Londei M, Quaratino S, Maiuri L. 
Lysosomal accumulation of gliadin p31–43 peptide induces oxidative 
stress and tissue transglutaminase-mediated PPARgamma 
downregulation in intestinal epithelial cells and coeliac mucosa. Gut. 
2010;59(3):311–9.  
34. Schultheiss TE, Stephens LC. Invited review: permanent radiation 
myelopathy. Br J Radiol. 1992;65(777):737–53.  
35. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol. 
1991;12(1):45–62.  
36. Schultheiss TE. Cerebral radiation necrosis: regarding Schultheiss et al 
IJROBP 31:1093–1112;1995. Int J Radiat Oncol Biol Phys. 
1995;32(4):1269.  
37. Tofilon PJ, Fike JR. The radioresponse of the central nervous system: a 
dynamic process. Radiat Res. 2000;153(4):357–70.  
38. Montgomery DL. Astrocytes: form, functions, and roles in disease. Vet 
Pathol. 1994;31(2):145–67.  
39. Wilson JX. Antioxidant defense of the brain: a role for astrocytes. Can J 
Physiol Pharmacol. 1997;75(10–11):1149–63.  
40. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, 
Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF. Knockout of 
glutamate transporters reveals a major role for astroglial transport in 
excitotoxicity and clearance of glutamate. Neuron. 1996;16(3):675–
86.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
31 
 
41. Brown DR. Neurons depend on astrocytes in a coculture system for 
protection from glutamate toxicity. Mol Cell Neurosci. 
1999;13(5):379–89.  
42. Vorotnikova E, Rosenthal RA, Tries M, Doctrow SR, Braunhut SJ. Novel 
synthetic SOD/catalase mimetics mitigate capillary endothelial cell 
apoptosis. Radiation Res. 2010;173:748–59.  
43. Pong K, Doctrow SR, Huffman K, Adinolfi CA, Baudry M. Attenuation of 
staurosporine-induced apoptosis, oxidative stress, and mitochondrial 
dysfunction by synthetic superoxide dismutase and catalase mimetics, 
in cultured cortical neurons. Exp Neurol. 2001;171(1):84–97.  
44. Otterson MF, Nie L, Link BJ, Schmidt JL, Rafiee P. Protective effect of 
EUK-207 on irradiated human intestinal microvascular endothelial cells 
(HIMEC) Abstracts, Experimental Biology. 2011 
45. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial 
function and dysfunction: molecular mechanisms and therapeutic 
opportunities. Antioxid Redox Signal. 2008;10(10):1713–65.  
46. Marks LB, Yu X, Vujaskovic Z, Small WJ, Folz R, Anscher MS. Radiation-
induced lung injury. Seminars in Radiation Oncology. 2003;13:333–
45.  
47. Fleckenstein K, Zgonjanin L, Chen L, Rabbani Z, Jackson IL, Thrasher B, 
Kirkpatrick J, Foster WM, Vujaskovic Z. Temporal onset of hypoxia and 
oxidative stress after pulmonary irradiation. Int J Radiat Oncol Biol 
Phys. 2007;68(1):196–204.  
48. Finkelstein JN, Johnston CJ, Baggs R, Rubin P. Early alterations in 
extracellular matrix and transforming growth factor beta gene 
expression in mouse lung indicative of late radiation fibrosis. Int J 
Radiat Oncol Biol Phys. 1994;28:621–31.  
49. Langan AR, Khan MA, Yeung IW, Van Dyk J, Hill RP. Partial volume rat 
lung irradiation: the protective/mitigating effects of Eukarion-189, a 
superoxide dismutase-catalase mimetic. Radiother Oncol. 
2006;79(2):231–8.  
50. Srinivasan V, Doctrow S, Singh VK, Whitnall MH. Evaluation of EUK-189, a 
synthetic superoxide dismutase/catalase mimetic as a radiation 
countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271–
90.  
51. Limoli CL, Giedzinski E, Baure J, Doctrow SR, Rola R, Fike JR. Using 
superoxide dismutase/catalase mimetics to manipulate the redox 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
32 
 
environment of neural precursor cells. Radiat Prot Dosimetry. 
2006;122(1–4):228–36.  
52. Mahmood J, Jelveh S, Calveley V, Zaidi A, Doctrow S, Hill R. Mitigation of 
radiation-induced lung injury by genestein and EUK-207. Int J Rad 
Biol. 2011 in press.  
53. Ghosh SN, Wu Q, Mader M, Fish BL, Moulder JE, Jacobs ER, Medhora M, 
Molthen RC. Vascular injury after whole thoracic x-ray irradiation in 
the rat. Int J Radiat Oncol Biol Phys. 2009;74(1):192–9.  
54. Zhang R, Ghosh SN, Zhu D, North PE, Fish BL, Morrow NV, Lowry T, 
Nanchal R, Jacobs ER, Moulder JE, Medhora M. Structural and 
functional alterations in the rat lung following whole thoracic 
irradiation with moderate doses: injury and recovery. Int J Radiat Biol. 
2008;84(6):487–97.  
55. Ghosh SN, Zhang R, Fish BL, Semenenko VA, Li XA, Moulder JE, Jacobs 
ER, Medhora M. Renin-Angiotensin system suppression mitigates 
experimental radiation pneumonitis. Int J Radiat Oncol Biol Phys. 
2009;75(5):1528–36.  
56. Gao F, Ghosh SN, Kma L, Wu Q, Molthen RC, Fish BL, Moulder JE, 
Doctrow SR, Medhora M. Angiotensin converting enzyme (ACE) 
inhibitors in combination with EUK-207 for mitigation of radiation 
pneumonitis. Abstracts, 56th Annual Meeting of the Radiation Research 
Society; 2010. PS1.50. 
57. Molthen RC, Wu Q, Fish BL, Jacobs ER, Moulder JE, Doctrow SR, Medhora 
M. Mitigation of radiation-induced pneumonitis and pulmonary vascular 
injury using combined therapy: angiotensin converting enzyme 
inhibitors and superoxide dismutase (SOD) mimetics. Abstracts, 56th 
Annual Meeting of the Radiation Research Society; 2010. PS1.28. 
58. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, Wolfe LF, 
Brizio-Molteni L, Veno P. Control of radiation-induced pneumopathy 
and lung fibrosis by angiotensin-converting enzyme inhibitors and an 
angiotensin II type 1 receptor blocker. Int J Radiat Biol. 
2000;76(4):523–32.  
59. Williams JP, Hill RP, Haston C, Johnston C, Miller J, Zimmerman C, 
Hernady E, Reed C, Finkelstein JN. A combined therapeutic approach 
to pulmonary mitigation following a radiological event. Abstract, 56th 
Annual Meeting of the Radiation Res. Society; 2010. PS1.61. 
60. Cohen E, Moulder J. In: Cancer and the Kidney. Cohen E, editor. Oxford 
University Press; Oxford: 2011. pp. 193–204. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
33 
 
61. Moulder JE, Fish BL, Cohen EP. ACE inhibitors and AII receptor 
antagonists in the treatment and prevention of bone marrow 
transplant nephropathy. Curr Pharm Des. 2003;9(9):737–49.  
62. Cohen EP, Fish BL, Moulder JE. Mitigation of radiation injuries via 
suppression of the renin-angiotensin system: emphasis on radiation 
nephropathy. Curr Drug Targets. 2010;11(11):1423–9.  
63. Cohen EP, Fish BL, Irving AA, Rajapurkar MM, Shah SV, Moulder JE. 
Radiation Nephropathy is not Mitigated by Antagonists of Oxidative 
Stress. Radiat Res. 2009;172(2):260–4.  
64. Doctrow SR, Damphousse CA, Fish B, Huffman K, Jourdan M, Lazorova Z, 
Moulder J, Rosenthal RA. Synthetic superoxide dismutase/catalase 
mimetics to mitigate radiation-induced normal tissue damage. Rad. 
Res. 55th Annual Meeting; 2009. Abstract S1403:26. 
65. Lenarczyk M, Cohen EP, Fish BL, Irving AA, Sharma M, Driscoll CD, 
Moulder JE. Chronic oxidative stress as a mechanism for radiation 
nephropathy. Radiat Res. 2009;171(2):164–72.  
66. Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JA, Juckett 
MB, Moulder JE. Captopril to mitigate chronic renal failure after 
hematopoietic stem cell transplantation: a randomized controlled trial. 
Int J Radiat Oncol Biol Phys. 2008;70(5):1546–51.  
67. Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G, 
Ymamkawa M, Moses G, Bouchard P, Hayes LL, Bedrosian C, Dorner 
AJ. Defining mechanisms of action of interleukin-11 on the progression 
of radiation-induced oral mucositis in hamsters. Oral Oncol. 
2000;36(4):373–81.  
68. Sonis ST, Lindquist L, Vugt AV, Stewart AA, Stam K, Qu GY, Iwata KK, 
Haley JD. Prevention of chemotherapy-induced ulcerative mucositis by 
TGF-beta. Cancer Research. 1994;54:1135–38.  
69. Murphy CK, Fey EG, Watkins BA, Wong V, Rothstein D, Sonis ST. Efficacy 
of superoxide dismutase mimetic M40403 in attenuating radiation-
induced oral mucositis in hamsters. Clin Cancer Res. 
2008;14(13):4292–7.  
70. Rosenthal RA, Huffman KD, Fisette LW, Damphousse CA, Callaway WB, 
Malfroy B, Doctrow SR. Orally available Mn porphyrins with superoxide 
dismutase and catalase activities. J Biol Inorg Chem. 2009;14(6):979–
91.  
71. Salvemini D, Wang ZQ, Zweier JL, Samouilov A, Macarther H, Misko TP, 
Currie MG, Cuzzocrea S, Sikorski JA, Riley DP. A nonpeptidyl mimic of 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
34 
 
superoxide dismutase with therapeutic activity in rats. Science. 
1999;286:304–306.  
72. Roy S, Khanna S, Nallu K, Hunt TK, Sen CK. Dermal wound healing is 
subject to redox control. Mol Ther. 2006;13(1):211–20.  
73. Muller K, Meineke V. Radiation-induced alterations in cytokine production 
by skin cells. Exp Hematol. 2007;35(4 Suppl 1):96–104.  
74. De Loecker W, Van der Schueren E, Stas ML, Doms D. The effects of x-
irradiation on collagen metabolism in rat skin. Int J Radiat Biol Relat 
Stud Phys Chem Med. 1976;29(4):351–8.  
75. Rudolph R, Vande Berg J, Schneider JA, Fisher JC, Poolman WL. Slowed 
growth of cultured fibroblasts from human radiation wounds. Plast 
Reconstr Surg. 1988;82(4):669–77.  
76. Goldschmidt H, Sherwin WK. Reactions to ionizing radiation. J Am Acad 
Dermatol. 1980;3(6):551–79.  
77. Gorodetsky R, Mou XD, Fisher DR, Taylor JM, Withers HR. Radiation effect 
in mouse skin: dose fractionation and wound healing. Int J Radiat 
Oncol Biol Phys. 1990;18(5):1077–81.  
78. Jourdan MM, Olasz EB, Moulder JE, Fish BL, Mader M, Schock A, Morrow 
N, Semenenko V, Doctrow SR, Lazarova Z. Mitigation of combined 
radiation and skin wound injury by SOD/catalase mimetic EUK-207. 
Rad. Res. 55th Annual Meeting; 2009. Abstract PS1.35:64. 
79. Lopez A, Wu X, Olasz EB, Lazar J, Sells R, Fish BL, Mader M, Schock AM, 
Althouse BJ, Moulder JE, Lazarova Z. Gene Expression Profiling in 
Irradiated Skin. Radiat Res Society Abstracts. 2010:PS1. 
80. Jourdan M, Lopez A, Olasz E, Moulder J, Fish B, Mäder M, Schock A, 
Althouse B, Doctrow S, Lazarova Z. Effect of superoxide dismutase 
(SOD)/catalase mimetic EUK-207 on the radiation-induced skin injury. 
Journal of Investigative Dermatology. 2010;(Suppl 1s):S2. 
81. Kumar S, Kolozsvary A, Kohl R, Lu M, Brown S, Kim JH. Radiation-induced 
skin injury in the animal model of scleroderma: implications for post-
radiotherapy fibrosis. Radiat Oncol. 2008;3:40–47.  
82. Sen CK, Roy S. Redox signals in wound healing. Biochim Biophys Acta. 
2008;1780(11):1348–61.  
83. Luo JD, Wang YY, Fu WL, Wu J, Chen AF. Gene therapy of endothelial 
nitric oxide synthase and manganese superoxide dismutase restores 
delayed wound healing in type 1 diabetic mice. Circulation. 
2004;110(16):2484–93.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
35 
 
84. Demianenko IA, Vasilieva TV, Domnina LV, Dugina VB, Egorov MV, 
Ivanova OY, Ilinskaya OP, Pletjushkina OY, Popova EN, Sakharov IY, 
Fedorov AV, Chernyak BV. Novel mitochondria-targeted antioxidants, 
“Skulachev-ion” derivatives, accelerate dermal wound healing in 
animals. Biochemistry (Mosc) 2010;75(3):274–80.  
85. Meunier B, Cosledan F. Orally bioavailable low molecular weight 
metalloporphyrins. Eukarion, Inc: World Intellectual Property 
Organization; 2005. (PCT application number 20060241095) 
86. Liang LP, Huang J, Fulton R, Day BJ, Patel M. An orally active catalytic 
metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine neurotoxicity in vivo. J Neurosci. 
2007;27(16):4326–33.  
87. Trova MP, Gauuan PJ, Pechulis AD, Bubb SM, Bocckino SB, Crapo JD, Day 
BJ. Superoxide dismutase mimetics. Part 2: synthesis and structure-
activity relationship of glyoxylate- and glyoxamide-derived 
metalloporphyrins. Bioorg Med Chem. 2003;11(13):2695–707.  
88. Rabbani ZN, Batinic-Haberle I, Anscher MS, Huang J, Day BJ, Alexander 
E, Dewhirst MW, Vujaskovic Z. Long-term administration of a small 
molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, 
protects lungs from radiation-induced injury. Int J Radiat Oncol Biol 
Phys. 2007;67(2):573–80.  
89. Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Reboucas JS, 
Batinic-Haberle I, Vujaskovic Z. Early and late administration of MnTE-
2-PyP5+ in mitigation and treatment of radiation-induced lung 
damage. Free Radic Biol Med. 2010;48(8):1034–43.  
90. Declercq L, Sente I, Hellemans L, Corstjens H, Maes D. Use of the 
synthetic superoxide dismutase/catalase mimetic EUK-134 to 
compensate for seasonal antioxidant deficiency by reducing pre-
existing lipid peroxides at the human skin surface. Int J Cosmet Sci. 
2004;26(5):255–63.  
91. Gonzalez PK, Doctrow SR, Malfroy B, Fink MP. Role of oxidant stress and 
iron delocalization in acidosis-induced intestinal epithelial 
hyperpermeability. Shock. 1997;8(2):108–14.  
92. Bruce AJ, Malfroy B, Baudry M. Beta-amyloid toxicity in organotypic 
hippocampal cultures: protection by EUK-8, a synthetic catalytic free 
radical scavenger. Proc Natl Acad Sci (USA) 1996;93:2312–2316.  
93. Robert A, Loock B, Momenteau M, Meunier B. Catalase modeling with 
metalloporphyrin complexes having an oxygen ligand in a proximal 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
36 
 
position. Comparison with complexes containing a proximal nitrogen. 
Inorg Chem. 1991;30:706–711. 
94. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian 
organs. Physiol Rev. 1979;59(3):527–605.  
95. Reboucas JS, Spasojevic I, Batinic-Haberle I. Pure MnTBAP is not a 
superoxide dismutase mimic in aqueous systems: a case of structure-
activity relationship as a watchdog mechanism in experimental 
therapeutics and biology. Free Radic Biol Med. 2007;43(Suppl 1):S26.  
96. Dabrowiak J. Metals in Medicine. Wiley; NY: 2010.  
97. Sessler JL, Doctrow SR, McMurry TJ, Lippard SJ. Medicinal Inorganic 
Chemistry. American Chemical Society; NY: 2005.  
98. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-
specific MR contrast agents: role in imaging the liver and biliary tree. 
Radiographics. 2009;29(6):1725–48.  
99. Orrell RW. AEOL-10150 (Aeolus) Curr Opin Investig Drugs. 2006;7(1):70–
80.  
100. Salvemini D, Riley DP. Nonpeptidyl mimetics of superoxide dismutase in 
clinical therapies for diseases. Cell Mol Life Sci. 2000;57(11):1489–92.  
101. Noel F, Ijichi A, Chen JJ, Gumin GJ, Tofilon PJ. X-ray-mediated reduction 
in basic fibroblast growth factor expression in primary rat astrocyte 
cultures. Radiat Res. 1997;147(4):484–9.  
102. Gong B, Chen Q, Almasan A. Ionizing radiation stimulates mitochondrial 
gene expression and activity. Radiat Res. 1998;150(5):505–12.  
103. Poot M, Zhang YZ, Kramer JA, Wells KS, Jones LJ, Hanzel DK, Lugade 
AG, Singer VL, Haugland RP. Analysis of mitochondrial morphology and 
function with novel fixable fluorescent stains. J Histochem Cytochem. 
1996;44(12):1363–72.  
104. Galante YM, Hatefi Y. Resolution of complex I and isolation of NADH 
dehydrogenase and an iron--sulfur protein. Methods Enzymol. 
1978;53:15–21.  
105. Hatefi Y, Stiggall DL. Preparation and properties of succinate: ubiquinone 
oxidoreductase (complex II) Methods Enzymol. 1978;53:21–7.  
106. Ragan CI, Hatefi Y. Isolation of the iron-sulfur-containing polypeptides of 
NADH: oxidoreductase ubiquinone. Methods Enzymol. 1986;126:360–
9.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 4 (May 2011): pg. 359-372. DOI. This article is © Bentham Science 
Publishers and permission has been granted for this version to appear in e-Publications@Marquette. Bentham Science 
Publishers does not grant permission for this article to be further copied/distributed or hosted elsewhere without the 
express permission from Bentham Science Publishers. 
37 
 
 
Fig 1. Structures of salen Mn complexes: EUK-8, EUK-134, EUK-189 and 
EUK-207 
SOD and catalase activities, cytoprotective, and other properties of EUK-207 [17, 20] 
and the non-cyclized salen Mn complexes [5] have been described. The structures of 
the non- cyclized salen Mn complexes are: EUK-8, R=H, X=Cl; EUK-134, R = 
methoxy, X = acetoxy; EUK-189, R = ethoxy; X = acetoxy; EUK-207: OAc = acetoxy 
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Fig 2. Plasma levels of EUK-207 and EUK-189 following sc injection in rats 
Compounds (50 mg/kg and 62.5 mg/kg, respectively) were given as a single sc 
injection to WAG/RijCmcr rats and blood samples collected by orbital bleeding, 
collected into heparinized tubes. Plasma was extracted and quantitated for salen Mn 
complexes using LC- MS/MS as described previously [70]. Mean ± SD of n = 4 and 5, 
respectively. EUK-189 was undetectable at the last time point. 
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Fig 3. Radiation-induced mitochondrial abnormalities in rat astrocytes 
Rat astrocytes were cultured and exposed to ionizing radiation as described previously 
[101] A. ATP levels, assayed 4 days after irradiation using the luciferin/luciferase 
assay [102]. B. Mitochondrial mass, assayed 4 days after irradiation, using 
MitoTracker Green fluorescence measured with flow cytometry, as described [103]. 
Data are means ± SEM for n = 3; * indicates significantly different from unirradiated 
group (p<0.05). 
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Fig 4. Dose-dependent mitigation of respiratory chain effects in irradiated 
astrocytes by EUK-134 
Rat astrocytes were cultured and exposed to ionizing radiation as described for Fig. 3. 
EUK-134 was added immediately after irradiation, where indicated. On day 4 after 
irradiation, cells were harvested and respiratory chain complex activities measured as 
previously described for Complex I [104], Complex II [105], and Complex III [106]. Y 
axis indicates percent of the activity of the unirradiated control cells. Data are means 
± SEM for n=3. ** indicates significantly different from unirradiated (no EUK-134); * 
indicates significantly different from 30 Gy (no EUK-134) (p<0.05). 
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Fig 5. Time course of EUK-134 mitigation of mitochondrial effects in 
irradiated astrocytes  
Experiment was conducted as described for Fig 4, except that EUK-134 (50 uM) was 
added at the indicated time, in hours, after irradiation. * indicates significantly 
different from 30 Gy (no EUK-134). 
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Fig. 6. Breathing rates in rat lung injury model 
Breathing rate (mean breaths per minute) is given as a function of time after 
irradiation (10 Gy) for rats receiving no radiation (Control), radiation only (IRR) or 
radiation plus EUK-207 (IRR + EUK). Additional experimental details are described in 
the text and in the original study [52]. Drug treatments started immediately after 
irradiation and finished at 14 weeks. Each point represents the mean (±SEM) for all 
rats available for analysis at the different times. Statistical analysis (Tukey’s method, 
p<0.05) showed that the breathing rate in IRR + EUK rats did not differ from that of 
controls and that both differed from IRR. 
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Fig 7. Nucleic acid oxidation (8OHdG levels) in rat lung injury model 
Experimental details of the lung injury model, drug treatment, and statistical analysis 
are as described for Fig 6. Lung tissue was extracted and analyzed by 
immunohistochemistry for 8- OHdG as described [52]. The assays were performed at 
0, 4, 8, 14 and 28 weeks following irradiation. Percent positivity is the ratio of positive 
pixels/total number of positive and negative pixels in the tissue section (air spaces 
excluded). Each bar (A) or each point (B) represents the mean (±SEM). The 8OHdG 
levels in the EUK+IRR treated group was significantly lower than in IRR, and did not 
differ from that of the Control group, at all time points following irradiation (4 - 28 
wks). 
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Fig 8. Collagen synthesis (hydroxyproline content) in rat lung injury model 
Experimental details of the lung injury model and drug treatment are as described for 
Fig 6. Hydroxyproline content (μg of hydroxyproline/100 mg of wet lung tissue) was 
determined as described [52] in lung tissue collected at 28 weeks following irradiation. 
Each bar represents the mean (±SEM). Data from unirradiated controls were obtained 
from lungs from rats with ages corresponding to the time of radiation (age 7–8 wks), 
“young” and 28 wks later, “old”. The hydroxyproline content of the “Radiation only” 
group was significantly higher than that of the other groups, which did not differ from 
one another. 
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Fig 9. EUK-207 mitigates radiation induced loss of angiotensin converting 
enzyme (ACE) activity in the rat lung 
Experiment in WAGRijCmcr rats subjected to TBI (11 Gy) followed by BMT was 
conducted as described in the text and ACE activity was measured in isolated perfused 
lungs 6 wks after irradiation as described. Total lung ACE activity is represented as the 
mean surface area product [ml/min] based on a spectrophotometrically monitored 
substrate cleavage [53]. The data are means ± SEM, for n= 9 (No radiation), 7 (11 
Gy), and 8 (11 Gy+EUK-207). * indicates significant difference from the 11 Gy group 
(one way ANOVA followed by Bonferroni’s t test). 
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Fig 10. Mitigation of radiation renal injury by EUK-207 but not EUK-189 
WAG/RijCmcr rats were subjected to TBI (9 Gy) followed by BMT and renal injury 
monitored as described in the text. Salen Mn complexes were administered by 
continuous sc infusion for 12 wks, beginning 3 wk after irradiation, as described in the 
text. The infusion was based on constant volume delivery, resulting in a dose of 8 to 
10 mg/kg-day. The data are mean BUN for n=6 and error bars indicate 95% 
confidence intervals. * is significantly different from TBI only (p<0.01, Mann-Whitney). 
Normal range of BUN in these rats is 18 to 22 mg/dL. 
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Fig 11. Mitigation of radiation renal injury by EUK-207 and captopril 
Experiment was conducted as described for Fig 10, except that the TBI dose was 10 
Gy. EUK-207 was given as described for Fig 10. Captopril (12 - 15 mg/kg-day) was 
administered in the drinking water over the same treatment period. The data are 
mean BUN for n=6 to 7 and error bars indicate 95% confidence intervals. *, # denotes 
difference from TBI only (p<0.01, #p<=.07, Mann-Whitney). Normal range of BUN in 
these rats is 18 to 22 mg/dL. 
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Fig 12. Improvement of radiation-induced ulcerative mucositis in the 
hamster by EUK-189 
The hamster mucositis model and scoring system are described in the text and in a 
previous study [69]. EUK-189 dosing was topical (T) or subcutaneous (SC), using 
protocols described in the text. The figure shows the percent animal days with a 
mucositis score ≥ 3. Group sizes were n = 8. * indicates statistically different from 
corresponding vehicle control group (chi square). The T and SC control groups were 
not significantly different from one another. 
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Table 1. Summary of properties of selected synthetic SOD/catalase 
mimetics 
Relevant properties, discussed further at various places in the text, are 
summarized here. EUK-207 and EUK-189 are salen Mn complexes (Fig 1) and EUK-
423, EUK-418, and EUK-451 are orally available Mn porphyrin complexes, with 
structures as reported by Rosenthal et al. [70]. Superoxide dismutase (SOD), catalase 
(CAT) and peroxidase (PX) activities were assayed as described [70]. SOD activity is 
represented as an IC50 (μM), so lower values represent higher SOD activity. CAT and 
PX are expressed as reaction rates (μM/minute). LogP values were determined by 
octanol-water partitioning, as described [70]. Stability to synthetic gastric solution 
(SGF), determined as described [70], shows the percent of compound remaining after 
90 min at 37°C. Stability to EDTA, determined as described [17], shows the percent of 
compound remaining after incubation at ambient temperature in a 114-fold molar 
excess of EDTA for 3.2 or 70 hr, as indicated. All data are reprinted from the cited 
articles. Error bars represent SD for triplicate determinations. nd indicates not done 
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Table 2. Mitigation of radiation renal injury with EUK-207 (sc daily) 
Renal injury was induced in WAG/Rij rats using TBI/BMT as described in the text. The 
radiation dose was 10 Gy. Rats treated with EUK-207, at the indicated daily doses, 
received sc injections beginning 48 hr after irradiation and continuing for 10 wks. 
Proteinurea (UP/UC) was measured at 9 and 17 weeks. BUN was measured at 9, 17, 
21 weeks and at sacrifice. Blood pressure (BP) was measured at 17 weeks. The 
median survival and range are shown in the first data column. The data for other 
parameters are means (with 95% confidence levels); n = 9–10. Results of statistical 
testing (Mann-Whitney, corrected for multiple comparisions): 
 
a p<0.05 vs age-matched normal; 
b p<0.05 vs TBI alone; all other comparisons p>0.10 
* time to BUN=120 (with range) 
 
 
 
 
 
 
 
 
 
